SCHEMBL5997248

SCHEMBL5997248

O=C(CCP)c1c(Cl)c(Cl)cc(Cl)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.36
HSD17B10 Q99714 4/20 0.36
TSHR P16473 4/20 0.36
CASP1 P29466 1/20 0.36
CYP3A4 P08684 3/20 0.35
HSPA5 P11021 2/20 0.34
MAPK1 P28482 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HIF1A Q16665 2/20 0.33
NPC1 O15118 1/20 0.33
USP2 O75604 1/20 0.33
EGFR P00533 1/20 0.33
LMNA P02545 1/20 0.33
ESR1 P03372 1/20 0.33
ERBB2 P04626 1/20 0.33
CYP1A2 P05177 1/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
PGR P06401 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5994135 0.82 CES2 (0.34)
SCHEMBL5995456 0.82 DPP4 (0.36) HSD17B10TSHRCYP3A4MAPK1MEN1
SCHEMBL5997001 0.79 THRB (0.38) HPGDHSD17B10TSHRCASP1CYP3A4
SCHEMBL5995317 0.76 ALDH1A1 (0.44) HPGDHSD17B10TSHRMEN1KMT2A
SCHEMBL5997498 0.76 HIF1A (0.33) HPGDHSD17B10TSHRCASP1HSPA5
SCHEMBL5996812 0.75 FEN1 (0.53) HPGDTSHRCYP3A4MEN1KMT2A
SCHEMBL27614441 0.74 HPGD (0.39) HPGDHSD17B10TSHRCASP1CYP3A4
SCHEMBL5997559 0.72 ALDH1A1 (0.41) HSD17B10TSHRCYP3A4MAPK1MEN1
SCHEMBL11788268 0.69 FASN (0.45) HPGDHSD17B10TSHRCASP1CYP3A4
SCHEMBL27595815 0.69 MEN1 (0.34) MEN1KMT2ALMNAMAPTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109250-B2 Multimer forms of acylphosphines and their derivatives CIBA SPECIALTY CHEMICALS CORP. (US) 2006-09-19 US disclosed
US-7026017-B2 Photoinitiators for acrylic esters; reacting an acyl halide with a metal benzoyl phosphine; cable coatings, screen printing stencils, resist materials, colour filters, electrical encapsulation CIBA SPECIALTY CHEMICALS CORPORATION (US) 2006-04-11 US disclosed
US-6969733-B2 Photoinitiators CIBA SPECIALTY CHEMICALS CORPORATION (US) 2005-11-29 US disclosed
US-20050004247-A1 Multimer forms of acylphosphines and their derivatives CIBA SPECIALTY CHEMICALS CORP. 2005-01-06 US disclosed
EP-1446410-A1 MULTIMER FORMS OF ACYLPHOSPHINES AND THEIR DERIVATIVES Ciba SC Holding AG (CH) 2004-08-18 EP disclosed
US-20030139485-A1 Photoinitiators WOLF JEAN-PIERRE (CH) 2003-07-24 US disclosed
US-20030130370-A1 Photoinitiators for acrylic esters; reacting an acyl halide with a metal benzoyl phosphine; cable coatings, screen printing stencils, resist materials, colour filters, electrical encapsulation WOLF JEAN-PIERRE (CH) 2003-07-10 US disclosed
WO-2003044030-A1 MULTIMER FORMS OF ACYLPHOSPHINES AND THEIR DERIVATIVES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139485-A1 Photoinitiators DHCR24, NR1I3, CBR1 HPGD 2368/4885HSD17B10 611/4885TSHR 1096/4885
US-20030130370-A1 Photoinitiators for acrylic esters; reacting an acyl halide with a metal benzoyl phosphine; cable coatings, screen printing stencils, resist materials, colour filters, electrical encapsulation SMARCC1, ARPC5L, DHCR24 HPGD 3137/4885HSD17B10 435/4885TSHR 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.